C12N 2760/18452
Relating to complementing cells and packaging systems for producing virus or viral
Official title: relating to complementing cells and packaging systems for producing virus or viral particles
C12N2760/18452 (Relating to complementing cells and packaging systems for producing virus or viral) appears on 8 US grants and 15 published applications in this corpus.
Search patents in C12N- Granted patents
- 8
- Published applications
- 15
- Assignees
- 10
- Inventors
- 20
- Latest grant
- 10 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 2 |
| 2017 | 0 | 0 |
| 2018 | 2 | 2 |
| 2019 | 1 | 0 |
| 2020 | 2 | 2 |
| 2021 | 0 | 2 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 2 | 2 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions10 Dec 2024US 12,163,150 B2Centre National De La Recherche Scientifique
- Lassa vaccine7 May 2024US 11,976,305 B2Centre National De La Recherche Scientifique
- Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions6 Oct 2020US 10,793,877 B2Centre National De La Recherche Scientifieque
- Compositions and methods for enhancing virus replication31 Mar 2020US 10,604,741 B2Turnstone Limited Partnership
- Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions31 Dec 2019US 10,519,466 B2Centre National de la Recherche Scientiflque
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector27 Aug 2026US 2026/0250709 A1Repli-Tech Co., Ltd.
- Reverse genetics system for feline morbillivirus2 Oct 2025US 2025/0304921 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector19 Sep 2024US 2024/0309335 A1Repli-Tech Co., Ltd.
- Recombinant measles virus5 Sep 2024US 2024/0293533 A1
- Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions8 Apr 2021US 2021/0102220 A1Centre National De La Recherche Scientifique
Most cited
By later US patents
- Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions8US 9,012,214 B2Centre National De La Recherche Scientifique · 2015
- Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions2US 10,519,466 B2Centre National de la Recherche Scientiflque · 2019
- Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions2US 10,793,877 B2Centre National De La Recherche Scientifieque · 2020
- Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions1US 9,914,937 B2Centre National De La Recherche Scientifique · 2018